Cytox launches breakthrough genetic biomarker research assay for Alzheimer’s disease...

Simple blood-based test will help reduce screening failure in clinical trials and assist drug discovery 22nd July 2016, Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced the launch of its research use variaTECT™ genetic biomarker test for assessing Alzheimer’s disease (AD) risk. The variaTECT™ SNP…

read more

Blog

Invested Business? Invest in Marketing

With so much research and development taking place in the early stages of your...

read more

Planning for reopening – how to accelerate out of lockdown

The government’s roadmap out of the lockdown is currently going to plan and we...

read more
Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now

×